Zealand Pharma A/S (CPH:ZEAL)
304.90
-7.70 (-2.46%)
May 19, 2026, 12:14 PM CET
Zealand Pharma Revenue
Zealand Pharma had revenue of 34.00M DKK in the quarter ending March 31, 2026, with 325.00% growth. This brings the company's revenue in the last twelve months to 9.24B, up 16,519.65% year-over-year. In the year 2025, Zealand Pharma had annual revenue of 9.21B with 14,598.86% growth.
Revenue (ttm)
9.24B
Revenue Growth
+16,519.65%
P/S Ratio
2.39
Revenue / Employee
16.99M
Employees
544
Market Cap
22.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.21B | 9.15B | 14,598.86% |
| Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
| Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
| Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
| Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 327.80B |
| Coloplast | 28.05B |
| H. Lundbeck | 25.52B |
| Genmab | 25.29B |
| Demant | 22.97B |
| GN Store Nord | 16.60B |
| ALK-Abelló | 6.56B |
| Embla Medical | 6.21B |
Zealand Pharma News
- 11 days ago - Zealand Pharma Launches DKK 1.3 Billion Buyback Plan, Stock Soars - GuruFocus
- 11 days ago - Zealand Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 12 days ago - Zealand Pharma Launches $200 Mln Share Buyback Program - Nasdaq
- 12 days ago - Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance - Reuters
- 19 days ago - Zealand Pharma upgraded to Buy from Hold at SEB Equities - TheFly
- 19 days ago - Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3 - TheFly
- 20 days ago - Zealand Pharma Announces Positive Topline Phase 3 Results For Weight-Loss Drug Survodutide - Nasdaq
- 4 weeks ago - Zealand Pharma appoints Eric Rojas as VP, head of IR - TheFly